These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7647158)

  • 21. Intrabronchial surfactant application in cases of inhalation injury: first results from patients with severe burns and ARDS.
    Pallua N; Warbanow K; Noah EM; Machens HG; Poets C; Bernhard W; Berger A
    Burns; 1998 May; 24(3):197-206. PubMed ID: 9677021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Natural surfactant preparation in complex therapy of acute respiratory distress syndrome in adults following open-heart surgeries].
    Bautin AE; Khubulava GG; Osovskikh VV; Rozenberg OA
    Anesteziol Reanimatol; 2003; (4):55-7. PubMed ID: 14524023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined surfactant therapy and inhaled nitric oxide in rabbits with oleic acid-induced acute respiratory distress syndrome.
    Zhu GF; Sun B; Niu SF; Cai YY; Lin K; Lindwall R; Robertson B
    Am J Respir Crit Care Med; 1998 Aug; 158(2):437-43. PubMed ID: 9700118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental models of acute respiratory distress syndrome: clinical relevance and response to surfactant therapy.
    Kobayashi T; Tashiro K; Cui X; Konzaki T; Xu Y; Kabata C; Yamamoto K
    Biol Neonate; 2001 May; 80 Suppl 1():26-8. PubMed ID: 11359042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pulmonary surfactant function following endotoxin: effects of exogenous surfactant treatment.
    Picone A; Gatto LA; Nieman GF; Paskanik AM; Lutz C
    Shock; 1996 Apr; 5(4):304-10. PubMed ID: 8721392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is surfactant a promising additive drug in ALI/ARDS-patients?
    Schultz MJ; Kesecioglu J
    Curr Drug Targets; 2004 Jul; 5(5):445-8. PubMed ID: 15216910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contrast media inhibit exogenous surfactant therapy in rats with acute respiratory distress syndrome.
    Kesecioglu J; Haitsma JJ; Schultz MJ; den Heeten GJ; Lachmann B
    Clin Physiol Funct Imaging; 2006 Mar; 26(2):120-6. PubMed ID: 16494603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The future of surfactant therapy during ALI/ARDS.
    Lewis JF; Veldhuizen RA
    Semin Respir Crit Care Med; 2006 Aug; 27(4):377-88. PubMed ID: 16909371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of acute (Adult) respiratory distress syndrome. The holy grail of surfactant therapy.
    Taeusch HW
    Biol Neonate; 2000 May; 77 Suppl 1():2-8. PubMed ID: 10828579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion (VA/Q) mismatch in a model of acute lung injury.
    Schermuly RT; Günther A; Weissmann N; Ghofrani HA; Seeger W; Grimminger F; Walmrath D
    Am J Respir Crit Care Med; 2000 Jan; 161(1):152-9. PubMed ID: 10619813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The pulmonary surfactant system: physiology, pathologies associated with its alteration and exogenous administration as therapeutic and diagnostic agent].
    Calmanovici G; Boccio J; Lysionek A; Salgueiro M; Caro R; Hager A; de Paoli T; Zubillaga M
    Acta Physiol Pharmacol Ther Latinoam; 1998; 48(4):175-90. PubMed ID: 9914807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exogenous surfactant administration by asymmetric high-frequency jet ventilation in experimental respiratory distress syndrome.
    Calkovska A; Sevecova-Mokra D; Javorka K; Petraskova M; Adamicova K
    Croat Med J; 2005 Apr; 46(2):209-17. PubMed ID: 15849841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aerosolized medications for altering lung surface active properties.
    MacIntyre NR
    Respir Care; 2000 Jun; 45(6):676-83. PubMed ID: 10894460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surfactant supplementation in the lung.
    Anzueto A
    Respir Care Clin N Am; 2002 Jun; 8(2):211-36. PubMed ID: 12481816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exogenous surfactant therapy for ARDS.
    Maruscak A; Lewis JF
    Expert Opin Investig Drugs; 2006 Jan; 15(1):47-58. PubMed ID: 16370933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome.
    Weg JG; Balk RA; Tharratt RS; Jenkinson SG; Shah JB; Zaccardelli D; Horton J; Pattishall EN
    JAMA; 1994 Nov; 272(18):1433-8. PubMed ID: 7933425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 99mTc-DTPA-surfactant inhalation in adult respiratory distress syndrome (ARDS): a new diagnostic-therapeutic tool.
    Todisco T; Cosmi E; Dottorini M; Baglioni S; Eslami A; Fedeli L; Palumbo R
    J Aerosol Med; 1992; 5(2):113-22. PubMed ID: 10147686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of pulmonary surfactant in the development and treatment of adult respiratory distress syndrome.
    Holm BA; Matalon S
    Anesth Analg; 1989 Dec; 69(6):805-18. PubMed ID: 2686493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of exogenous surfactant in acute lung injury.
    Lewis JF; Brackenbury A
    Crit Care Med; 2003 Apr; 31(4 Suppl):S324-8. PubMed ID: 12682460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of exogenous surfactant to treat patients with acute high-permeability lung edema.
    Spragg RG; Richman P; Gilliard N; Merritt TA; Robertson B; Curstedt T
    Prog Clin Biol Res; 1989; 308():791-6. PubMed ID: 2675070
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.